Skip to content
value.today

Agentix Corp.

AGTX
$31 Mlast known market cap, Jan 2022 — no current value
Compare
World rank
—
no current market cap
Revenue
—
For year ending March-2026
Net income
$-0 M
SEC filing
Employees
—

Agentix Corp. in brief

Agentix Corp. is a listed company in the Biotechnology industry, based in Dana Point, California, USA. Its last known market value was $31 M (January 2022); there is no current figure.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Agentix Corp.

The Company was incorporated in the State of Nevada on April 18, 2013 and has established a fiscal year end of March 31. Effective June 17, 2019, we changed our name from FairWind Energy, Inc. to Agentix Corp. and to better reflect the new focus of our business. We are a clinical development stage corporation with a focus on pharmaceutical treatments in the metabolic disease space and have not yet generated or realized meaningful revenues from our business.

Until recently, our business plan focused on the design, engineering and manufacturing of composite products, specifically the supply products to the oil and gas industry. However, on May 28, 2020, entered into a Share Exchange Agreement with GSL Healthcare, Inc., a Nevada corporation, and the holders of common stock of GSL Healthcare, which consisted of two stockholders. The closing date occurred on June 1, 2020.

From the company's annual report filed with the US SEC: read the report

Agentix Corp. timeline

2 events, 2014–2019
  1. 2014
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2019
  4. ✎
    Renamed Agentix Corp.
    Formerly FairWind Energy Inc..

Events of Agentix Corp. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Aug 2017: revenue —, net income $-0M—FY17Fiscal year ending Aug 2018: revenue —, net income $-43M—FY18Fiscal year ending Aug 2019: revenue —, net income $-0M—FY19Fiscal year ending Mar 2022: revenue $0M, net income $-3M$0MFY22Fiscal year ending Mar 2023: revenue —, net income $-1M—FY23Fiscal year ending Mar 2024: revenue —, net income $-1M—FY24Fiscal year ending Mar 2025: revenue —, net income $-1M—FY25Fiscal year ending Mar 2026: revenue —, net income $-0M—FY26
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Mar 2026——$-0M$-0M—
Mar 2025——$-1M$-1M—
Mar 2024——$-1M$-1M—
Mar 2023——$-1M$-1M—
Mar 2022$0M—$-3M$-3M—
Aug 2019——$-0M$-0M—
Aug 2018——$-0M$-43M—
Aug 2017——$-0M$-0M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Mar 2026$-0M——$-0.01—
Mar 2025$-0M——$-0.01—
Mar 2024$-0M——$-0.01—
Mar 2023$-0M————
Mar 2022$-0M——$-0.04—
Aug 2019$-0M——$-6.45—
Aug 2018$-0M——$-3875.40—
Aug 2017$-0M——$-0.06—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024: revenue —, net income $-0M—Dec ’24Three months to Mar 2025 (from the annual report): revenue —, net income $-0M—Mar ’25Three months to Jun 2025: revenue —, net income $-0M—Jun ’25Three months to Sep 2025: revenue —, net income $-0M—Sep ’25Three months to Dec 2025: revenue —, net income $-0M—Dec ’25Three months to Mar 2026 (from the annual report): revenue —, net income $-0M—Mar ’26Three months to Jun 2026: revenue —, net income $-0M—Jun ’26Three months to Sep 2026: revenue —, net income $-0M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Agentix Corp. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-0 M
Net income
$-0 M

For year ending March-2026 · source: SEC filing

Balance sheet

Total assets
$0 M
Total liabilities
$4 M
Total equity
$-4 M

As of March-2026

Insider trading at Agentix Corp.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
6
since
Agentix Corp.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Grays Peak Ventures LLC10% ownerBuy+767,000——2.19 MForm 4
filed Michael WinterhalterPres, Treasurer & Secretary, DirectorBuy+150,000——150,000Form 4
filed Grays Peak Ventures LLC10% ownerOther+1.41 M$20.44$28.8 M1.42 MForm 4
filed Michael WinterhalterPres, Treasurer & Secretary, DirectorSell-10,015$20.44$205 K0Form 4
filed Grays Peak Ventures LLC10% ownerBuy+9,358$20.44—14,070Form 4
filed Michael Winterhalter10% ownerSell-8,433$20.44$172 K10,035Form 4
filed Scott B. StevensPresident, Director, 10% ownerBuyindirect+9,358$20.44$191 K14,070Form 4
filed Scott ThomasDirectorGrant or award+5,000——5,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Agentix Corp. scorecard#

Passes 1 of the 7 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.01 vs -0.01Diluted EPS -0.01 in fiscal 2025 against -0.01 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$0 MNet income -$0 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 3
    • ✗Short-term assets cover short-term liabilities0.0×Current ratio 0.00 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-5.6×Operating income -5.6 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year0.0%Diluted shares down 0.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Agentix Corp.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Agentix Corp.: statements by fiscal year
PeriodTrendFY 2025to Mar 31, 2026FY 2024to Mar 31, 2025FY 2023to Mar 31, 2024FY 2022to Mar 31, 2023FY 2021to Aug 31, 2021FY 2019to Aug 31, 2019FY 2018to Aug 31, 2018FY 2017to Aug 31, 2017FY 2016to Aug 31, 2016FY 2015to Aug 31, 2015
Income statement
Revenue———01.2——2.34328
Cost of revenue———00.6——1.41.42.0
Gross profit———00.7——0.94226
Research and development125181175712365———3.728
General and administrative6870347140664.08.8242336
Operating expenses4455137451,3721,341121134335334201
Operating income−445−513−745−1,372−1,341−121−134−334−292r−175
Interest expense and finance costs8043211.6—112513——
Net interest income——————2513——
Other non-operating income (expense)—−54160r2.0−0.0—42,655473.2r—
Income before tax−486−567−585−1,374−1,340−133−42,789−381−296—
Income tax00000—————
Income from continuing operations————————−292−175
Net income including minority interests—567585r−1,374——————
Net income attributable to shareholders−486−567−585−1,374−1,340−133−42,789−381−296−175
Earnings per share, basic————-0.04-6.45-3,875.40r-0.06-0.05-0.03
Earnings per share, diluted-0.01-0.01-0.01—-0.04-6.45-3,875.40r-0.06-0.05-0.03
Shares, weighted average (basic)————————6.06.0
Shares, weighted average (diluted)404040—350.00.0r6.06.06.0
Balance sheet
Cash and cash equivalents0.84.56.5121.80.12.13.70.613
Inventory————49—————
Other current assets096100249——————
Current assets0.8100106261510.12.13.70.613
Property, plant and equipment—————00.10.40.70.9
Other intangible assets—————————3.4
Total assets0.8100106261510.12.37.11.318
Accounts payable7169699621,0571217.2——2.82.3
Current liabilities3,5963,2052,6672,511607419.74.73.77.4r
Non-current liabilities00000854667——
Total liabilities3,5963,2052,6672,51160712655723.7—
Retained earnings−7,007−6,522−5,954−5,369−1,704−44,033r−43,898−1,109−728−432r
Shareholders' equity−3,596−3,104−2,560−2,249−556−126−53−65−2.410r
Total liabilities and equity0.8100106261510.12.37.11.318
Shares outstanding40404040352.6r0.0r6.06.06.0
Cash-flow statement
Cash from operating activities−109−125−110−89−421−62−52−76−13−187
Cash from investing activities00000——−9.5——
Debt issued11010016350——————
Debt repaid—0−700——————
Shares issued——050180————65
Cash from financing activities11010093100180605089—65
Exchange-rate effect on cash−5.623120.8——————
Change in cash−3.7−2.1−5.812−241—−1.63.1−13−122
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Agentix Corp.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Acquisition or sale completed 2 · Directors and officers 3 · Material agreement 2

Agentix Corp.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Acquisition or sale completed8-K
Material agreement8-K
Directors and officers8-K
Material agreement8-K
Acquisition or sale completed8-K/A
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Jun 14, 2022

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Agentix Corp.🇺🇸$31 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 7, 2022 (last known)
Annual results:
For year ending March-2026
Balance sheet:
As of March-2026
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Agentix Corp.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Agentix Corp.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Agentix Corp.? Suggest a correction